Quince Therapeutics surges 53% after hiring LifeSci Capital for reverse merger review
Quince Therapeutics engaged LifeSci Capital as financial advisor to explore restructuring and strategic alternatives including a reverse merger. The stock jumped 53% to $0.34 after closing at $0.23 as investors assessed its failed Phase 3 NEAT trial, $5.8 M cash balance, and sub-$1 share delisting threat.
1. Advisor Engagement
Quince engaged New York–based LifeSci Capital as its exclusive financial advisor to support restructuring activities and evaluate strategic alternatives, including a potential reverse merger, as outlined in its recent SEC filing.
2. Phase 3 NEAT Trial Failure
The NEAT trial, a randomized, double-blind, placebo-controlled Phase 3 study of lead candidate eDSP in ataxia-telangiectasia, failed to meet both primary and secondary endpoints, halting advancement of the drug.
3. Financial Position and Delisting Risk
As of December 31, 2025, Quince held $5.8 M in cash, $11.9 M in short-term investments and had €16.4 M outstanding on an unsecured European Investment Bank credit line. Its share price has remained below $1.00 since January 29, creating potential Nasdaq delisting concerns.
4. Market Reaction
After closing regular trading down 63% at $0.23, the stock rallied 53% to $0.34 in after-hours, yielding a $12.6 M market cap and an RSI of 28.6. The sharp rebound underscores extreme oversold conditions, though volatility remains high.